HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Vlach, J. Articles by Pitha, P. M. Search for Related Content PubMed PubMed Citation Articles by Vlach, J. Articles by Pitha, P. M. Agricola Articles by Vlach, J. Articles by Pitha, P. M.

Hexamethylene bisacetamide activates the human immunodeficiency virus type 1 provirus by an NF-B-independent mechanism

¹ Oncology Center
and² Department of Molecular Biology and Genetics, The Johns Hopkins University, Baltimore, Maryland 21231, U.S.A.

Expression of the human immunodeficiency virus type 1 (HIV-1) provirus in T lymphocytic and monocytic cells can be induced by treatment with hexamethylene bisacetamide (HMBA). The induction occurs at the transcriptional level within 1 to 3 h after the addition of the drug, and is not associated with detectable changes in the binding of transcription factors to the enhancer, TATA box or other regulatory regions of the HIV-1 long terminal repeat (LTR). Using the 5' deletion mutants of HIV-1 LTR controlling the expression of the chloramphenicol acetyltransferase gene, we found that the deletion of the B enhancer did not affect HIV-1 inducibility, whereas the deletion of the Sp1 binding sites abolished transcriptional activation. However, the presence of the HIV-1 LTR Sp1 binding sites in the context of the heterologous promoter did not induce responsiveness to HMBA. We conclude that HMBA increases transcription through the secondary modification of the basal transcription complex suggesting the existence of a regulatory pathway that circumvents the requirement for the induction of NF-B or other DNA-specific binding proteins.

Received 3 March 1993; accepted 15 June 1993.

This article has been cited by other articles:

				X. Contreras, M. Schweneker, C.-S. Chen, J. M. McCune, S. G. Deeks, J. Martin, and B. M. Peterlin Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells J. Biol. Chem., March 13, 2009; 284(11): 6782 - 6789. [Abstract] [Full Text] [PDF]

				N. He, A. C. Pezda, and Q. Zhou Modulation of a P-TEFb Functional Equilibrium for the Global Control of Cell Growth and Differentiation Mol. Cell. Biol., October 1, 2006; 26(19): 7068 - 7076. [Abstract] [Full Text] [PDF]

				V. Klichko, N. Archin, R. Kaur, G. Lehrman, and D. Margolis Hexamethylbisacetamide Remodels the Human Immunodeficiency Virus Type 1 (HIV-1) Promoter and Induces Tat-Independent HIV-1 Expression but Blunts Cell Activation J. Virol., May 1, 2006; 80(9): 4570 - 4579. [Abstract] [Full Text] [PDF]